Corticosteroid injections, often regarded as a rapid solution for troublesome acne, are traditionally performed in clinical settings before significant life events such as weddings, proms, or red carpet appearances. Now, there’s an intriguing shift towards an at-home treatment option that could change the landscape of acne care.
Indomo, an innovative acne prescription brand co-founded by experts from telemedicine, beauty, and medical device industries, is developing a device called the ClearPen. This corticosteroid injector aims to facilitate convenient and effective acne treatment in the comfort of one’s home. The ClearPen resembles an EpiPen in design and is still navigating the clinical trial landscape; its founders are optimistic that it will soon be available through prescriptions, pending successful completion of the lengthy trial process ahead.
Rick Bente, the CEO of Indomo, expresses confidence in the potential impact of this device, noting, “Nothing has significantly changed the treatment landscape for inflamed lesions since Starface.” This would be a considerable advancement in acne treatment. Indomo’s leadership team includes seasoned professionals, such as a former Allergan executive and dermatology specialists from prestigious institutions like Harvard and Stanford.
The venture has garnered $25 million in funding from investors like Foresite Capital and Polaris Partners, with Abraham’s venture capital firm, Atomic, playing a vital role in supporting the initiative. Bente also pointed out that the clinical trial phases often span several years, though no specific launch date has been projected.
One of the most compelling features of the ClearPen is its user-friendly design. The anticipated pricing is expected to be on par with that of conventional in-office treatments. The device incorporates advanced pen injector technology, equipped with a notably shorter needle tailored specifically to address acne lesions effectively.
Jack Abraham lauded the ClearPen as potentially the “first significant innovation in acne treatment since Accutane.” With the backing of Hims & Hers, there is a potential for high visibility within the telemedicine space. The goal is not only to facilitate in-store prescriptions but also to reach patients who may otherwise lack easy access to dermatological services.
Bente elaborated on this vision, stating, “This offers a way for dermatologists to extend their care beyond office visits.” Particularly for those who have limited access to specialists, advancements in telehealth could play a crucial role in bridging the gap between patient needs and professional guidance.
